SGMO Stock SGMO is expected to report earnings to rise+43% to -19 cents per share on May 09

A.I.dvisor
at Tickeron.com
05/08/24
Loading...
SGMO - Sangamo Therapeutics
Sangamo Therapeutics Earnings Graph
Q1'24
Est.
$-0.19
Q4'23
Missed
by $0.08
Q3'23
Missed
by $0.27
Q2'23
Missed
by $0.31
Q1'23
Est.
$0.12
The last earnings report on December 31 showed earnings per share of -34 cents, missing the estimate of -26 cents. P/B Ratio (1.339) is normal, around the industry mean (10.346). P/E Ratio (0.000) is within average values for comparable stocks, (113.451). SGMO's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.447). SGMO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (0.529) is also within normal values, averaging (231.135). With 1.66M shares outstanding, the current market capitalization sits at 110.99M.
View a ticker or compare two or three
SGMODaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of transcription factors in the regulation of genes

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
501 Canal Boulevard
Phone
+1 510 970-6000
Employees
405
Web
https://www.sangamo.com